Details About Generic Salt ::  Bromocri

Main Medicine Class:: Antiparkinson   

(BROE-moe-KRIP-teen MEH-sih-LATE)

Parlodel,  Alti-Bromocriptine, Apo-Bromocriptine, Parlodel

Class: Antiparkinson

Drugs Class ::

 Action Stimulates dopamine receptors in the corpus striatum, relieving parkinsonian symptoms. Inhibits prolactin, which is responsible for lactation, and lowers elevated blood levels of growth hormone in acromegaly.

Indications for Drugs ::

 Indications Treatment of hyperprolactinemia-associated disorders (amenorrhea with or without galactorrhea, infertility, hypogonadism) in patients with prolactin-secreting adenomas; therapy for female infertility associated with hyperprolactinemia; treatment of acromegaly; therapy for Parkinson’s disease (idiopathic or post-encephalitic). Unlabeled use(s): Treatment of hyperprolactinemia associated with pituitary adenomas; therapy for neuroleptic malignant syndrome; treatment of cocaine addiction.

Drug Dose ::

 Route/Dosage

Hyperprolactinemia-Associated Disorders

INITIAL DOSE: PO 1.25 to 2.5 mg/day; 2.5 mg may be added as tolerated every 3 to 7 days until optimum response. (Dosage range: 2.5 to 15 mg/day).

Acromegaly

INITIAL DOSE: PO 1.25 to 2.5 mg for 3 days at bedtime; may be increased by 1.25 to 2.5 mg as tolerated every 3 to 7 days until optimum response occurs. Dosage range: 20 to 30 mg/day, not to exceed 100 mg/day.

Parkinson’s Disease

INITIAL DOSE: PO 1.25 mg bid titrated individually. Dosage range: 10 to 40 mg/day, not to exceed 100 mg/day.

Contraindication ::

 Contraindications Sensitivity to ergot alkaloids; severe ischemic heart disease or peripheral vascular disease; pregnancy.

Drug Precautions ::

 Precautions

Pregnancy: Pregnancy category undetermined. Lactation: Contraindicated in nursing women. Children: Safety and efficacy in children < 15 yr not established. Pituitary tumors: Evaluate pituitary before treatment to determine if tumor is present. Symptomatic hypotension: Do not administer to postpartum patients until blood pressure normalizes. Use caution in patients with pre-eclampsia and in those who have received other drugs that may alter blood pressure. Acromegaly: Cold-sensitive digital vasospasms and severe GI bleeding from peptic ulcers have been reported in patients with acromegaly; institute appropriate treatment. Possible tumor expansion has occurred; monitor patient’s condition and discontinue treatment if necessary. Parkinson’s disease: Safe use > 2 yr has not been established. Periodic evaluation of hepatic, hematopoietic, CV and renal functions is necessary.

Drug Side Effects ::

 Adverse Reactions

CV: Hypotension (including orthostatic); syncope; hypertension; stroke, digital vasospasm. CNS: Headache; dizziness; fatigue; lightheadedness; fainting; drowsiness; psychosis; seizures; abnormal involuntary movements; hallucinations; confusion; ataxia; insomnia; depression; vertigo; “on-off” phenomenon. EENT: Visual disturbances, nasal congestion. GI: Nausea; vomiting; abdominal cramps; constipation; diarrhea; anorexia; indigestion/dyspepsia; GI bleeding. RESP: Shortness of breath; pulmonary infiltrates; pleural effusion; pleural thickening. OTHER: Exacerbation of Raynaud’s syndrome; asthenia.

Drug Mode of Action ::  

 Action Stimulates dopamine receptors in the corpus striatum, relieving parkinsonian symptoms. Inhibits prolactin, which is responsible for lactation, and lowers elevated blood levels of growth hormone in acromegaly.

Drug Interactions ::

 Interactions

Dopamine antagonists (eg, phenothiazines, butyrophenones, metoclopramide): May reduce bromocriptine efficacy. Erythromycin: May increase bromocriptine serum levels.

Drug Assesment ::

 Assessment/Interventions

• Obtain patient history, including drug history and any known allergies.
• Monitor BP prior to and during drug therapy. Severe hypotension may occur. Have patient remain supine for several hours after initial dose.
• Observe for lessening of symptoms of Parkinson’s disease (eg, rigidity, akinesia, tremors, pill rolling, shuffling gait, mask facies) prior to and during drug therapy.
• Assess breasts for decrease in engorgement.
• Assess for exacerbation of Raynaud’s syndrome (eg, muscle cramps in hands or feet, cold feet).
• Ensure safety and assess for risk of falls if dizziness occurs.

Drug Storage/Management ::

 Administration/Storage

• Give with milk or meals to reduce gastric distress. Initial dose is usually given at bedtime because of adverse CNS reactions (eg, dizziness, fainting).
• Tablet may be crushed if patient has difficulty swallowing.
• If dose must be delayed for > 4 hr, omit dose. Do not give double dose.
• Response to bromocriptine varies with individuals. Titrate dose to balance risks/benefits.
• Store at room temperature in tightly-closed container.

Drug Notes ::

 Patient/Family Education

• Tell patient not to skip doses or take double doses.
• Caution patient not to discontinue drug suddenly, and to avoid rapid recurrence of original symptoms. Explain that dosage will be tapered slowly before stopping use of drug.
• Advise women of childbearing age to use nonhormonal methods of birth control during therapy.
• Instruct patient to inform physician immediately if pregnancy is suspected.
• When used for infertility, instruct patient to obtain daily basal body temperatures to determine when ovulation occurs.
• Advise patients who are taking drug to suppress lactation that breast engorgement may occur as therapy is discontinued.
• Inform patient that side effects are common, especially during initial phase of therapy.
• Instruct patient to notify physician if increasing dyspnea or nasal congestion occurs.
• Caution patient to avoid sudden position changes to prevent orthostatic hypotension.
• Advise patient to avoid intake of alcoholic beverages.
• Advise patient that drug may cause drowsiness, and to use caution while driving or performing other tasks requiring mental alertness.

Disclaimer ::

The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.